Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 3/20 | 0.47 |
| ▸ | GPR6 | P46095 | 4/20 | 0.47 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | TYK2 | P29597 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6694725 | 0.85 | AURKA (0.45) | ADRA1DHTR1A | |
| SCHEMBL6699529 | 0.77 | TBK1 (0.44) | — | |
| SCHEMBL6712880 | 0.77 | FAAH (0.47) | JAK2JAK3FAAHJAK1GPR6 | |
| SCHEMBL6865185 | 0.77 | FAAH (0.60) | JAK2JAK3FAAHJAK1GPR6 | |
| SCHEMBL16932389 | 0.76 | FAAH (0.52) | JAK2JAK3FAAHJAK1GPR6 | |
| SCHEMBL7239878 | 0.76 | FAAH (0.49) | JAK2JAK3FAAHJAK1GPR6 | |
| SCHEMBL27760391 | 0.76 | OPRM1 (0.58) | JAK2JAK3FAAHGPR6CXCR3 | |
| SCHEMBL6698553 | 0.76 | FAAH (0.54) | FAAHDRD2CHRM4CHRM3 | |
| SCHEMBL6694937 | 0.76 | ITGB3 (0.56) | FAAHCHRM4CHRM3 | |
| SCHEMBL6702960 | 0.75 | MAPK8 (0.48) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | claimed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | claimed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | claimed |
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-01-15 | — | — | US | disclosed |
| EP-1289982-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APOB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096327-A1 | BIOISOSTERIC BENZAMIDE DERIVATIVES AND THEIR USE AS APoB-100 SECRETION INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009988-A1 | Bioisosteric bensamide derivatives and their use as apob-100 secretion inhibitors | APOB, APOL1, TTR | JAK2 3843/4885JAK3 4247/4885FAAH 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.